Pulmonx Corporation (LUNG) is a commercial-stage medical technology company and a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Its flagship product, the Zephyr Endobronchial Valve, is designed to treat patients with severe emphysema who remain profoundly symptomatic despite medical management. The Zephyr Valve received U.S. Food and Drug Administration (FDA) Premarket Approval following its designation as a "breakthrough device" and is commercially available in more than 25 countries, where it is included in global treatment guidelines.
The company's portfolio also includes the Chartis Pulmonary Assessment System, the LungTraX Platform, and StratX Lung Analysis Reports, which help physicians assess patients and identify target lobes for treatment. I keep an eye on LUNG for its exposure to a large, underpenetrated emphysema market, its recurring catheter-based procedure model, and its pipeline opportunity through AeriSeal, a potential market-expanding therapy. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, LUNG advanced approximately 35%, moving from a closing price near $1.96 on September 28, 2026, to roughly $2.64 in late October 2026. For much of October, the stock traded in a relatively narrow range between about $1.75 and $1.98 before surging in response to the company's third-quarter earnings report released on October 27. From what I see, this kind of move often signals a shift in sentiment when fundamentals start to align.
The broader quarterly trend has also been positive, with the stock up roughly 21% over the trailing three-month period, according to market data compiled around the earnings release. Despite the recent rebound, LUNG remained lower on a year-to-date basis, reflecting the challenges the company faced earlier in 2026 before its commercial turnaround began to take hold.
The primary catalyst was Pulmonx's third-quarter 2026 financial results. The company reported worldwide revenue of $22.8 million, up 6% year over year, representing its first return to global year-over-year growth since its current leadership team rejoined the company. U.S. revenue rose 7% to $14.9 million, while international revenue increased 5% to $7.9 million, or about 9% excluding China.
The results also showed meaningful progress toward profitability. Gross margin improved to 76% from 75%, operating expenses declined 18% to $24.9 million, and the adjusted EBITDA loss narrowed by nearly 60% to $3.5 million. The net loss shrank 40% to $8.4 million, or $0.19 per share, beating the consensus estimate of a $0.26 per-share loss, while revenue topped the roughly $21.9 million analyst consensus. One thing that stands out here is how quickly the cost discipline is translating into narrower losses.
Investor sentiment was further supported by analyst actions. Stifel raised its price target on Pulmonx to $4 from $2.50 while maintaining a Buy rating, and Canaccord Genuity reiterated a Buy recommendation. The company also announced that its China registration certificate had been renewed, allowing it to restart commercial activity in the region with shipments expected to resume by early next year. I’m watching this closely as China could add a meaningful tailwind.
Over the past quarter, LUNG's recovery has been driven by a multi-month operational reset. Management spent the year rebuilding its U.S. sales leadership team and filling open territories, and the company reported that substantially all open U.S. sales positions have now been filled. This contributed to the addition of eight new U.S. treating centers during the quarter and a return to U.S. revenue growth.
The company also restructured its credit facility earlier in 2026, extending debt maturity to 2031 and securing access to additional undrawn capital. Ongoing cost-reduction initiatives have lowered operating expenses and reduced expected cash burn, while clinical momentum—including five-year follow-up data from the LIBERATE pivotal trial and progress enrolling the CONVERT II IDE trial for AeriSeal—has reinforced the long-term growth narrative.
Looking ahead, investors are likely to focus on whether Pulmonx can sustain its return to growth. The company reiterated full-year 2026 revenue guidance of $90 million to $92 million and expects full-year gross margin of approximately 77%, with operating expenses guided to between $108 million and $109 million. The resumption of China shipments early next year represents a potential incremental revenue driver.
Additional factors to monitor include the pace of new U.S. treating center additions, continued progress enrolling the CONVERT II trial, and the company's ability to narrow losses and manage cash burn, which it expects to total roughly $22 million for 2026. Macroeconomic conditions, broader medical-device sector sentiment, and any changes in analyst estimates following the earnings report could also influence the stock's direction.
In my own research process, I often review Tickeron’s AI Trading Bots to see how automated strategies are performing across different market conditions. These tools allow me to compare quantitative approaches side by side and identify setups that align with the fundamentals I’m tracking. It’s been helpful for stress-testing ideas without overcomplicating the workflow, especially when evaluating names like LUNG that are in turnaround phases.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 202 similar instances where the Aroon Indicator formed such a pattern. In 185 of the 202 cases the stock moved lower. This puts the odds of a downward move at 90%.
The 10-day RSI Indicator for LUNG moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 27 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Moving Average Convergence Divergence Histogram (MACD) for LUNG turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 44 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on LUNG as a result. In 70 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
LUNG moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LUNG crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +7.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 214 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.805) is normal, around the industry mean (4.142). P/E Ratio (-2.226) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices